drugset
drugset / Trial / NCT06532643

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

NCT06532643 ↗

Phase 0 Recruiting 9 enrolled Shanghai First Song Biotechnology Co., LTD
NaSingle-groupOpen-labelTreatment

Summary

This study is an exploratory clinical trial of a single-center, open-label, single-dose treatment of anti-CD20/CD30-CAR-T cells in subjects with relapsed/refractory lymphoma.

Timeline

Start
2023-08-24
Primary completion
2025-09-01
Completion
2026-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CD20/CD30-CAR-T cells Cell therapy — Intravenous
Background Cyclophosphamide Other / unclassified 250 mg/m2 Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous

Indications

lymphoma